Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.50 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241582 | 1.00 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGA2BITGB5 | |
| SCHEMBL20488513 | 0.97 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGB8 | |
| SCHEMBL31241603 | 0.97 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGB8 | |
| SCHEMBL22893581 | 0.97 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGB8 | |
| SCHEMBL22893644 | 0.90 | ITGAV (0.54) | ITGAVITGB6ITGB3ITGB5ITGB8 | |
| SCHEMBL31241601 | 0.90 | ITGAV (0.54) | ITGAVITGB6ITGB3ITGB5ITGB8 | |
| SCHEMBL22893596 | 0.89 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGB8 | |
| SCHEMBL22893655 | 0.89 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGB8 | |
| SCHEMBL20486737 | 0.89 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGB8 | |
| SCHEMBL31241598 | 0.89 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210284640-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3760202-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| WO-2018160522-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB6 1/4885ITGB3 12/4885 |
| US-20210284640-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB6 1/4885ITGB3 11/4885 |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB6 1/4885ITGB3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.